OCS Stock Summary and Trading Ideas (Oculis Holding Ag - | NASDAQ:OCS)

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Oculis Holding Ag - trades on the NASDAQ stock market under the symbol OCS.

As of August 21, 2026, OCS stock price declined to $13.09 with 70,752 million shares trading.

OCS has a beta of 2.07, meaning it tends to be more sensitive to market movements. OCS has a correlation of 0.08 to the broad based SPY ETF.

OCS has a market cap of $756.40 million. This is considered a Small Cap stock.

Last quarter Oculis Holding Ag - reported $392,150 in Revenue and -$.20 earnings per share. This beat revenue expectation by $132,150 and exceeded earnings estimates by $.28.

In the last 3 years, OCS traded as high as $34.48 and as low as $9.05.

The top ETF exchange traded funds that OCS belongs to (by Net Assets): SBIO, BBC, ONEQ, GWX.

OCS has underperformed the market in the last year with a return of -26.5%, while the SPY ETF gained +21.7%. In the last 3 month period, OCS fell short of the market, returning -57.8%, while SPY returned +3.4%. However, in the most recent 2 weeks OCS has outperformed the stock market by returning +3.2%, while SPY returned -1.0%.

OCS support price is $12.74 and resistance is $13.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCS shares will trade within this expected range on the day.